Bonjour,
Here's my second look and summary of the European ME Alliance survey and report on ME/CFS. It's a huge document and I can only read a little at a time. Plus I think that for those of you with this illness it's easier to understand in small amounts.
First of all you can check out the first part here.
You may also like to take a look at the interview done by David Tuller who interviewed the authors of the survey and report
Symptoms and severity
Severity
The survey used a severity scale of the ICC (International Consensus Criteria)
- mild (approx 50% reduction in pre-illness activity level)
- moderate ( mostly housebound)
- severe ( mostly bedridden)
- very severe (totally bedridden and need help with basic functions)
- better than mild but not recovered
- completely recovered
- 2.4% very severe
- 16.0% severe
- 53.8% moderate
- 24% mild
- 3.7% better than mild
- 0.2 % recovered
- more men than women had mild disease
- more women than men had moderate disease
- severe and very severe was a about the same for both
- the young tend to have a more severe form of the disease
- early onset is a risk factor for severe disease
- the most restrictive was symptom exacerbation after exertion (PEM)
- sensitivity to light, sound and smell
- 85% reported having at least one comorbidity
- the most common being IBS, allergies and fibromyalgia
- plus postural orthostatic tachycardia syndrome (POTS)
- hypermobility or Ehler Danlos syndrome
- hypermobile type (hEDS)
- thyroid problems
- diabetes
- mast cell activation syndrome (MCAS)
- 27% had one comorbidity
- 25% had two
- 48% had more than two
- 46% reported mainly deterioration
- 26% described a course of illness with initial fluctuations then deterioration
- 24% had experienced major fluctuations throughout the course of the illness
- 7% reported improvement
- only 9% reported improvement during the previous year
- 29% said they were stable during the previous year
- 18% had experienced large fluctuations during the previous year
- 44% reported deterioration in the last year
- biological factors, like age of onset, gender and type of trigger
- how well the disease is accepted by family and friends
- access to health care, social or financial benefits
- management strategies